Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Common Equity (2020 - 2024)

Historic Common Equity for Burning Rock Biotech (BNR) over the last 6 years, with Q3 2025 value amounting to $77.2 million.

  • Burning Rock Biotech's Common Equity fell 1641.78% to $77.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.2 million, marking a year-over-year decrease of 1641.78%. This contributed to the annual value of $79.6 million for FY2024, which is 2647.63% down from last year.
  • Per Burning Rock Biotech's latest filing, its Common Equity stood at $77.2 million for Q3 2025, which was down 1641.78% from $78.8 million recorded in Q2 2025.
  • Burning Rock Biotech's 5-year Common Equity high stood at $356.2 million for Q1 2021, and its period low was $77.2 million during Q3 2025.
  • Over the past 5 years, Burning Rock Biotech's median Common Equity value was $133.4 million (recorded in 2023), while the average stood at $170.5 million.
  • As far as peak fluctuations go, Burning Rock Biotech's Common Equity plummeted by 4291.74% in 2022, and later tumbled by 1555.83% in 2025.
  • Over the past 5 years, Burning Rock Biotech's Common Equity (Quarter) stood at $289.6 million in 2021, then tumbled by 42.0% to $167.9 million in 2022, then plummeted by 35.56% to $108.2 million in 2023, then fell by 26.48% to $79.6 million in 2024, then decreased by 2.98% to $77.2 million in 2025.
  • Its Common Equity stands at $77.2 million for Q3 2025, versus $78.8 million for Q2 2025 and $78.8 million for Q1 2025.